Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H ( (HK:2252) ) has provided an update.
Shanghai MicroPort MedBot announced that its flagship Toumai laparoscopic surgical robot has secured more than 200 commercial orders worldwide, with about 130 systems already installed across nearly 50 countries and regions. The order momentum underscores growing global recognition of Toumai’s clinical value and reliability among surgeons working in diverse healthcare systems and specialties.
Adoption has been particularly strong in emerging markets, with India and Brazil among countries ordering double-digit unit volumes, while developed markets like Spain and Australia are becoming new growth drivers. The system is also deepening its presence at individual medical centers, with dozens of hospitals performing over 100 procedures each and expanding use across disciplines from urology to pediatric and head and neck surgery.
Toumai has additionally advanced in remote surgery, having been approved for commercial use in nearly 10 countries and now covering areas with almost half of the world’s population. The platform has completed nearly 800 remote procedures in more than 20 countries with a reported 100% implementation success rate, reinforcing the company’s position in the rapidly evolving robotic and tele-surgery segment and signaling potential long-term benefits for patients, hospitals and investors despite the figures being based on preliminary internal data.
The most recent analyst rating on (HK:2252) stock is a Buy with a HK$30.00 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.
More about Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai MicroPort MedBot (Group) Co., Ltd. is a Chinese medical technology company specializing in robotic-assisted surgery systems, with its core product being the Toumai laparoscopic surgical robot. The group focuses on global deployment across both emerging markets such as India and Brazil and developed healthcare systems including Spain and Australia, targeting multi-specialty clinical applications and remote surgery capabilities.
Average Trading Volume: 6,388,589
Technical Sentiment Signal: Buy
Current Market Cap: HK$27.06B
For detailed information about 2252 stock, go to TipRanks’ Stock Analysis page.